B-type chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the Western world. Although B-CLL was long considered a homogeneous disease, recent studies indicate that B-CLL cases can be divided into two subgroups based on Ig V gene mutation status and also based on surface membrane expression of CD38. Patients in these two follow strikingly different clinical courses. Those patients in the unmutated Ig V gene group and those in the CD38+ experience a much more aggressive disease and almost invariably dying, despite extensive chemotherapy, much sooner than the patients in the mutated Ig V gene group or in the CD38- group. The reasons for these differences in clinical outcome are unknown. This proposal is designed to understand more precisely how these categories of B-CLL cases differ. We will address this by determining differences in the characteristics of the B-CLL cells, and some of the other immune cells, in these two groups. Specifically, we will determine: [1] the phenotypic and molecular features of B cell activation and differentiation that are unique to each B-CLL subgroup, [2] the biologic features that might explain the different clinical courses of the B-CLL subgroups, in particular whether the two subsets of B-CLL cells exhibit differences in immunologic properties such as cytokine production, antigen presentation, and cell signaling and apoptosis induction via the B cell receptor in conjunction with other signaling pathways, and [3] the patterns and levels of gene expression that distinguish the B-CLL subgroups, either unmanipulated or after BCR signaling, as measured by cDNA-based representation difference analyses and microarray gene chip technologies. We believe that the proposed studies will identify critical differences in cell maturation, immune function, and gene expression that will help clarify the reasons for their dramatically dissimilar clinical courses. Hopefully, these differences will provide important basic and clinical insights into this disease and suggest future prognostic and therapeutic approaches to it.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA087956-04S1
Application #
6935671
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Rosenfeld, Bobby
Project Start
2001-07-01
Project End
2005-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
4
Fiscal Year
2004
Total Cost
$62,866
Indirect Cost
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Chu, Charles C; Catera, Rosa; Hatzi, Katerina et al. (2008) Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112:5122-9
Catera, Rosa; Silverman, Gregg J; Hatzi, Katerina et al. (2008) Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 14:665-74
Cutrona, Giovanna; Colombo, Monica; Matis, Serena et al. (2008) Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica 93:413-22
McCarthy, Brian A; Boyle, Erin; Wang, Xue Ping et al. (2008) Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18). Mol Med 14:618-27
Damle, Rajendra N; Temburni, Sonal; Calissano, Carlo et al. (2007) CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110:3352-9
Chiorazzi, Nicholas (2007) Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 20:399-413
Dono, Mariella; Burgio, Vito Lelio; Colombo, Monica et al. (2007) CD5+ B cells with the features of subepithelial B cells found in human tonsils. Eur J Immunol 37:2138-47
Ghiotto, Fabio; Fais, Franco; Albesiano, Emilia et al. (2006) Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med 12:300-8
Ryan, Elizabeth P; Pollock, Stephen J; Kaur, Kuljeet et al. (2006) Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin Immunol 120:76-90
Chiorazzi, Nicholas; Ferrarini, Manlio (2006) Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematology Am Soc Hematol Educ Program :273-8, 512

Showing the most recent 10 out of 27 publications